Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Entrada Therapeutics, Inc. (TRDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Entrada Therapeutics Reports Second Quarter 2023 Financial Results"
05/10/2023 8-K Quarterly results
Docs: "Entrada Therapeutics Reports First Quarter 2023 Financial Results - $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 -"
03/06/2023 8-K Quarterly results
Docs: "Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results"
11/07/2022 8-K Quarterly results
Docs: "Entrada Therapeutics Reports Third Quarter 2022 Financial Results On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping amenable in the fourth quarter of 2022"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
12/09/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy